查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596679

脊髓性肌肉萎缩症药物市场：按类型、治疗方法、给药途径- 全球预测 2025-2030

Spinal Muscular Atrophy Treatment Market by Type (Type 1, Type 2, Type 3), Treatment (Drug Therapy, Gene Replacement Therapy), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

脊髓性肌肉萎缩症治疗市场2023年估值为16亿美元，预计到2024年将达到18.5亿美元，复合年增长率为15.40%，到2030年将达到43.7亿美元。

脊髓性肌肉萎缩症 (SMA) 治疗包括多种旨在控制和缓解 SMA 症状的治疗方法，SMA 是一种以肌肉退化和无力为特征的遗传性疾病。 SMA 治疗的必要性在于其进行性和对生活品质的影响，并且需要能够缓解症状和改善功能的治疗方法。最终用途涵盖医院、专科诊所和居家照护，包括基因替代疗法、口服药物和支持性护理。主要成长动力包括意识和诊断率的提高、基因研究的进步以及生物製药创新投资的增加。最近 FDA 的核准进一步刺激了市场扩张，并为新进入者打开了大门。个人化医疗方法的发展和更广泛的最先进治疗代表着一个重大的商机，利用这些前景需要强有力的战略伙伴关係和跨部门合作。然而，高昂的治疗成本、严格的监管环境以及发展中地区的患者准入有限等限制因素对市场成长构成了挑战。建议将早期诊断和基因编辑技术的进步作为创新的重点。公司可以从投资于了解疾病遗传背景的研究中受益，以便开发新的治疗性介入。经济问题可以透过寻求与医疗保健提供者和保险公司伙伴关係来协商更好的承保范围和定价模式来解决。 SMA 治疗市场具有动态性，深受医学研究和生物技术突破的影响。考虑到这些细微差别，公司必须保持敏捷，不断评估竞争格局和患者需求，并使创新与市场需求保持一致。儘管面临挑战，但透过策略研究计划和增强的以患者为中心的解决方案，市场具有强大的成长和转型潜力。

主要市场统计
基准年[2023] 16亿美元
预测年份 [2024] 18.5亿美元
预测年份 [2030] 43.7亿美元
复合年增长率（%） 15.40%

市场动态：快速发展的脊髓性肌肉萎缩症药物市场的关键市场洞察

供需的动态交互作用正在改变脊髓性肌肉萎缩症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 脊髓性肌肉萎缩症负担增加
    • 脊髓性肌肉萎缩症药物的优惠报销
    • 政府和非营利组织所进行的意识计画倡议
  • 市场限制因素
    • 成功治疗的时限有限
  • 市场机会
    • 研究并开发扩大脊髓性肌肉萎缩症治疗药物的潜在功效
    • 拓展网路药品通路
  • 市场挑战
    • 缺乏训练有素的专业人员

波特五力：驾驭脊髓性肌肉萎缩症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解脊髓性肌肉萎缩症药物市场的外在影响

外部宏观环境因素在塑造脊髓性肌肉萎缩症药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解脊髓性肌肉萎缩症治疗药物市场的竞争状况

对脊髓性肌肉萎缩症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脊髓性肌肉萎缩症药物市场供应商的绩效评估

FPNV 定位矩阵是评估脊髓性肌肉萎缩症药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为脊髓性肌肉萎缩症药物市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，对脊髓性肌肉萎缩症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 脊髓性肌肉萎缩症负担增加
      • 脊髓性肌肉萎缩症药物的优惠报销
      • 政府和非营利组织的意识计划工作
    • 抑制因素
      • 成功治疗的时限有限
    • 机会
      • 研究开发扩大脊髓性肌肉萎缩症治疗药物的潜在疗效
      • 拓展线上医药通路
    • 任务
      • 缺乏训练有素的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脊髓性肌肉萎缩症治疗药物市场：依类型

  • 类型1
  • 2型
  • 类型3
  • 类型4

第七章依治疗分類的脊髓性肌肉萎缩症药物市场

  • 药物治疗
  • 基因替代疗法

第八章脊髓性肌肉萎缩症药物市场：依给药途径

  • 椎管内的
  • 口服

第九章北美和南美脊髓性肌肉萎缩症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区脊髓性肌肉萎缩症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲脊髓性肌肉萎缩症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • Biogen Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Natera Inc.
  • NMD PHARMA A/S
  • Novartis AG
  • Novo Nordisk A/S
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0309FBC512FA

The Spinal Muscular Atrophy Treatment Market was valued at USD 1.60 billion in 2023, expected to reach USD 1.85 billion in 2024, and is projected to grow at a CAGR of 15.40%, to USD 4.37 billion by 2030.

Spinal Muscular Atrophy (SMA) treatment encompasses a range of therapies that aim to manage and mitigate the symptoms of SMA, a genetic disorder characterized by muscle degeneration and weakness. The necessity for SMA treatments stems from its progressive nature and the impact on quality of life, necessitating therapies that offer symptomatic relief and functional improvement. Applications include gene replacement therapies, oral medications, and supportive care regimes, with end-use spanning hospitals, specialty clinics, and home care settings. Key growth drivers include rising awareness and diagnosis rates, advancements in genetic research, and increased investment in biopharmaceutical innovation. Recent FDA approvals have further spurred market expansion, creating avenues for new entrants. The development of personalized medicine approaches and broader access to cutting-edge treatments represents significant opportunities, necessitating robust strategic partnerships and cross-sector collaboration to leverage these prospects. Nonetheless, limitations like high treatment costs, stringent regulatory landscapes, and limited patient accessibility in developing regions pose challenges to market growth. Advancements in early-stage diagnostics and gene-editing technologies are recommended as focal points for innovation. Companies can benefit from investments in research focused on understanding the disease's genetic underpinnings to develop novel therapeutic interventions. Exploring partnerships with healthcare providers and insurance companies to negotiate better coverage and pricing models could address affordability issues. The SMA treatment market is characterized by its dynamic nature, heavily influenced by breakthroughs in medical research and biotechnology. Given these nuances, companies must stay agile, continuously assessing the competitive landscape and patient needs to align their innovations with market demands. Despite challenges, the market holds strong potential for growth and transformation through strategic research initiatives and enhanced patient-centric solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 1.60 billion
Estimated Year [2024] USD 1.85 billion
Forecast Year [2030] USD 4.37 billion
CAGR (%) 15.40%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Spinal Muscular Atrophy Treatment Market

The Spinal Muscular Atrophy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of spinal muscular atrophy
    • Favorable reimbursements for spinal muscular atrophy treatment
    • Awareness programs initiatives by government and nonprofit organizations
  • Market Restraints
    • Limited time-window for successful therapy delivery
  • Market Opportunities
    • R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
    • Expansion of online medication distribution channels
  • Market Challenges
    • Shortage of trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Spinal Muscular Atrophy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Spinal Muscular Atrophy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Spinal Muscular Atrophy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Spinal Muscular Atrophy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Spinal Muscular Atrophy Treatment Market

A detailed market share analysis in the Spinal Muscular Atrophy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Spinal Muscular Atrophy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Spinal Muscular Atrophy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Spinal Muscular Atrophy Treatment Market

A strategic analysis of the Spinal Muscular Atrophy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Spinal Muscular Atrophy Treatment Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Biogen Inc., Catalyst Pharmaceuticals, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Natera Inc., NMD PHARMA A/S, Novartis AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Inc., Scholar Rock, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Spinal Muscular Atrophy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Type 1, Type 2, Type 3, and Type 4.
  • Based on Treatment, market is studied across Drug Therapy and Gene Replacement Therapy.
  • Based on Route of Administration, market is studied across Intrathecal and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of spinal muscular atrophy
      • 5.1.1.2. Favorable reimbursements for spinal muscular atrophy treatment
      • 5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Limited time-window for successful therapy delivery
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
      • 5.1.3.2. Expansion of online medication distribution channels
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of trained professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Spinal Muscular Atrophy Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Type 1
  • 6.3. Type 2
  • 6.4. Type 3
  • 6.5. Type 4

7. Spinal Muscular Atrophy Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Drug Therapy
  • 7.3. Gene Replacement Therapy

8. Spinal Muscular Atrophy Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intrathecal
  • 8.3. Oral

9. Americas Spinal Muscular Atrophy Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Spinal Muscular Atrophy Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. Biogen Inc.
  • 3. Catalyst Pharmaceuticals, Inc.
  • 4. Cytokinetics, Incorporated
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Ionis Pharmaceuticals, Inc.
  • 7. Natera Inc.
  • 8. NMD PHARMA A/S
  • 9. Novartis AG
  • 10. Novo Nordisk A/S
  • 11. PerkinElmer, Inc.
  • 12. Pfizer Inc.
  • 13. PTC Therapeutics, Inc.
  • 14. Scholar Rock, Inc.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023